Bilirubin (Total)
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- Bilirubin is one of the most potent endogenous antioxidants in the human body — a property largely unknown outside research circles. Bilirubin scavenges peroxyl radicals at nanomolar concentrations, inhibits lipid peroxidation and LDL oxidation, and appears to function as a chain-breaking antioxidant in lipid membranes. In vitro studies suggest bilirubin's antioxidant potency rivals vitamin C and vitamin E at physiological concentrations. This antioxidant activity is likely the primary mechanism behind the epidemiological evidence linking higher-normal bilirubin to lower cardiovascular risk.
- Gilbert's syndrome — the most common inherited cause of mildly elevated bilirubin — is associated with significantly lower cardiovascular disease risk. Gilbert's syndrome affects 5–10% of the population and results from a variant in the UGT1A1 gene that reduces bilirubin conjugation, causing mildly elevated unconjugated bilirubin (typically 1.0–3.0 mg/dL). Multiple cohort studies and Mendelian randomization analyses have found that people with Gilbert's syndrome have 30–50% lower rates of coronary artery disease and significantly lower cardiovascular mortality compared to the general population. This represents a natural human experiment showing bilirubin's cardioprotective role.
- The pattern of bilirubin elevation — direct vs. indirect — is clinically more important than the absolute value. Direct (conjugated) bilirubin elevation indicates hepatic or post-hepatic pathology — the liver has conjugated the bilirubin but it cannot be excreted normally, suggesting hepatocellular disease, cholestasis, or bile duct obstruction. Indirect (unconjugated) bilirubin elevation with normal direct bilirubin indicates pre-hepatic pathology (hemolysis — red blood cells breaking down faster than the liver can process) or a conjugation defect (Gilbert's syndrome, Crigler-Najjar). These two patterns have completely different clinical implications, making total bilirubin alone insufficient when elevation is found.
- Very low bilirubin is associated with higher oxidative stress in some analyses. The inverse relationship between bilirubin and cardiovascular risk extends below the midpoint of the normal range in several large studies. People with consistently low bilirubin (< 0.4–0.5 mg/dL) appear to have higher oxidative stress markers and somewhat higher cardiovascular risk compared to those in the mid-to-upper normal range. This observation suggests that optimizing antioxidant status through diet, exercise, and sleep — which modulates bilirubin levels — may have cardioprotective effects.
- Bilirubin is included in every CMP and liver function test, making it the most accessible antioxidant biomarker available. Unlike specialized antioxidant assays, bilirubin is automatically available on any panel that includes a CMP. Tracking bilirubin trends over years — noting whether it stays in the mid-to-upper normal range, rises to potentially pathological levels, or falls toward the low-normal range — adds longevity context to routine metabolic testing at no additional cost.
The Paradox of Bilirubin: Waste Product and Antioxidant
For most of medical history, bilirubin was considered nothing more than a metabolic waste product — the yellow byproduct of hemoglobin breakdown that accumulates to cause jaundice when liver or biliary function fails. Its measurement in the CMP served purely as a disease detection tool: normal means the liver is clearing heme waste efficiently; elevated means something is wrong.
This view has been substantially revised over the past three decades. Bilirubin is now recognized as one of the most potent endogenous antioxidants in human plasma — scavenging peroxyl radicals and inhibiting lipid peroxidation at physiological concentrations. The antioxidant capacity of bilirubin was first proposed by Stocker and colleagues in 1987 and has been extensively validated since. At nanomolar concentrations, bilirubin chain-breaks lipid peroxidation reactions, protecting LDL particles and cell membranes from oxidative damage. 1
The epidemiological evidence followed: study after study found that people with higher bilirubin levels — particularly in the mid-to-upper normal range — had lower rates of cardiovascular disease, atherosclerosis, and all-cause mortality. The natural experiment of Gilbert's syndrome — where a common genetic variant maintains chronically mildly elevated bilirubin — provided compelling quasi-experimental evidence of bilirubin's cardioprotective role.
Reading Bilirubin in a Longevity Context
The standard CMP flags total bilirubin above 1.2 mg/dL as elevated and worthy of investigation. From a longevity perspective, the interpretation is more nuanced:
A person with total bilirubin of 0.2 mg/dL has very low antioxidant capacity from this pathway. A person with 0.9 mg/dL has meaningfully more. A person with 1.5 mg/dL predominantly indirect bilirubin and entirely normal liver enzymes most likely has Gilbert's syndrome and an enviably low cardiovascular risk profile.
The key questions for any bilirubin elevation are: What fraction is direct vs. indirect? What are the other liver enzymes doing? Is the elevation stable or progressive? These questions distinguish the benign (Gilbert's, mildly elevated hemolysis from exercise, fasting effect) from the clinically significant (hepatocellular disease, biliary obstruction).
| Total Bilirubin | Longevity Interpretation | Next Step if Elevated |
|---|---|---|
| < 0.4 mg/dL | Low — possible reduced antioxidant protection | Optimize lifestyle; reassess |
| 0.6–1.2 mg/dL | Longevity optimal — associated with lowest CV risk | No action needed |
| 1.2–3.0 mg/dL (indirect-predominant) | Likely Gilbert's — generally favorable | Confirm with fractionated; check liver enzymes |
| > 1.2 mg/dL (direct-predominant) | Investigate liver/biliary cause | ALT, AST, ALP, GGT; liver imaging |
| Range Type | Value (mg/dL) | Notes |
|---|---|---|
| Standard Clinical Range | Total bilirubin: 0.1–1.2 mg/dL | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | 0.6–1.2 mg/dL (higher within normal range appears protective) |
Associated with reduced all-cause mortality and extended healthspan.
The longevity-optimal range for bilirubin inverts conventional interpretation: while values above 1.2 mg/dL may warrant investigation for liver or hemolytic pathology, values toward the upper portion of the normal range (0.6–1.2 mg/dL) are associated with lower cardiovascular risk in epidemiological studies. Values consistently below 0.4–0.5 mg/dL are associated with higher oxidative stress and cardiovascular risk in some analyses. Gilbert's syndrome — a benign genetic variant in UGT1A1 causing mildly elevated unconjugated bilirubin (typically 1.0–3.0 mg/dL) — is consistently associated with reduced cardiovascular disease, cancer, and all-cause mortality. The fractionated test is more informative than total bilirubin alone when values are elevated — predominantly indirect elevation with normal liver enzymes is reassuring (typically hemolysis or Gilbert's); predominantly direct elevation with elevated liver enzymes indicates hepatobiliary disease.
|
Already have your results? See what your Bilirubin (Total) and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
What is Gilbert's syndrome and should I be concerned if I have it?
Gilbert's syndrome is a benign inherited variation in the UGT1A1 gene that reduces the efficiency of bilirubin conjugation in the liver, causing mildly elevated unconjugated (indirect) bilirubin — typically 1.0–3.0 mg/dL, with values spiking to 3–4 mg/dL during fasting, illness, or physical stress. It affects 5–10% of the Western population, is more common in men, and causes no liver damage or functional impairment. The elevated bilirubin may cause mild yellowing of the skin or eyes (jaundice) during fasting or illness — a benign phenomenon that can be alarming without this context. Importantly, as described above, Gilbert's syndrome appears to be cardiovascularly protective, not harmful. People with Gilbert's syndrome have lower rates of coronary artery disease in large cohort studies. If your bilirubin is consistently mildly elevated (1.0–3.0 mg/dL) with normal ALT, AST, ALP, and GGT, and the elevation is predominantly unconjugated (indirect), Gilbert's syndrome is the most likely explanation — and from a longevity standpoint, it is a favorable finding.
When should elevated bilirubin prompt medical evaluation?
Elevated total bilirubin warrants clinical attention when: (1) it is above 2.5–3.0 mg/dL (the threshold where jaundice becomes clinically visible in the skin and sclera); (2) it rises progressively over serial measurements; (3) it is predominantly direct (conjugated) bilirubin, suggesting hepatocellular disease or biliary obstruction; or (4) it is accompanied by elevated liver enzymes (ALT, AST, ALP, GGT), which suggests active liver pathology. A single mild total bilirubin elevation (1.2–2.5 mg/dL) that is predominantly indirect, with completely normal liver enzymes and a normal complete blood count (ruling out hemolysis), very likely represents Gilbert's syndrome and requires no urgent intervention beyond confirmation. The fractionated bilirubin test cleanly distinguishes these scenarios.
How does fasting affect bilirubin levels?
Fasting reliably elevates bilirubin, particularly in people with Gilbert's syndrome but also to a lesser degree in the general population. A 24-hour fast can increase total bilirubin by 0.5–1.5 mg/dL above fed-state levels in susceptible individuals. The mechanism involves reduced glucuronyl transferase activity and altered intrahepatic bilirubin uptake during the fasted state. This means that bilirubin measured after an overnight fast (as most morning labs are drawn) may be modestly elevated compared to fed-state values. For people tracking bilirubin longitudinally, standardizing the fasting duration before draws (typically 8–10 hours) helps ensure consistent comparison.
Can exercise or other lifestyle factors lower bilirubin?
Several lifestyle factors modulate bilirubin levels. Regular aerobic exercise appears to lower bilirubin slightly, possibly through increased red blood cell turnover and enhanced hepatic bilirubin processing. Caloric restriction and weight loss — which improve liver function generally — tend to lower bilirubin when elevated from fatty liver. Smoking is associated with lower serum bilirubin levels, possibly through increased oxidative consumption of bilirubin by reactive oxygen species; this inverse relationship may partly explain smokers' higher cardiovascular risk (less bilirubin-mediated antioxidant protection). Some medications — most notably rifampin, which competes with bilirubin for hepatic uptake — transiently raise bilirubin; others (phenobarbital, which induces UGT1A1) lower it. For most adults with normal liver function, bilirubin is relatively stable on serial testing and does not require active intervention.